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Probing for and Quantifying Agonist Hydrogen Bonds in α6β2 Nicotinic 
Acetylcholine Receptors 
Post, Michael R.*, Henry A. Lester
‡
, Dennis A. Dougherty* 
*Division of Chemistry and Chemical Engineering; ‡Division of Biology and Biological 
Engineering, California Institute of Technology, Pasadena, CA  91125 USA 
 
Abstract 
 Designing subtype-selective agonists for neuronal nicotinic acetylcholine receptors 
(nAChR) is a challenging and significant goal aided by intricate knowledge of each subtype’s 
binding patterns.  We previously reported that in α6β2 receptors, acetylcholine makes a 
functional cation-π interaction with Trp149, but nicotine and TC299423 do not, suggesting a 
distinctive binding site.  This work explores hydrogen binding at the backbone carbonyl 
associated with α6β2 Trp149.  Substituting the i+1 residue, Thr150, with its α-hydroxy analogue 
(Tah) attenuates the carbonyl’s hydrogen bond accepting ability.  At α6(T150Tah)β2, nicotine 
shows a 24-fold loss of function, TC299423 shows a modest loss, and acetylcholine shows no 
effect.  Nicotine was further analyzed via a double-mutant cycle analysis utilizing N’-
methylnicotinium, which indicated a hydrogen bond in α6β2 with a ∆∆G of 2.6 kcal/mol. Thus, 
even though nicotine does not make the conserved cation-π interaction with Trp149, it still 
makes a functional hydrogen bond to its associated backbone carbonyl.  
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Introduction 
 The neuronal nicotinic acetylcholine receptors (nAChRs) are a group of pentameric 
ligand-gated ion channels (pLGICs) typically found at presynaptic terminals, where they 
modulate neurotransmitter release.
1–3
   There are eleven known subunits – α2 through α7, α9, 
α10 and β2 through β4 – that assemble into pentamers in different combinations.
4
  The different 
subunits share a common topology, and the agonist binding site is found in the extracellular 
binding region at the interface of two subunits. Different subunit combinations, i.e. different 
nAChR subtypes, display distinctive functions, pharmacologies, and localizations.
5
  While 
several subtypes are distributed throughout the brain (e.g. α4β2 and α7), others are concentrated 
in specific regions and only expressed by certain cell types.
6,7
  The α6-containing subtypes 
follow the latter pattern and are prominently expressed in dopaminergic neurons of the ventral 
tegmental area and the substantia nigra pars compacta, making them promising targets for both 
Parkinson’s disease and addiction.
8–10
  In addition, the α6 subunit is expressed in dorsal root 
ganglia, where it plays an important role in mechanical allodynia associated with neuropathies 
and inflammatory injuries.
11
 As such, insights into strategies for targeting drugs specifically to 
α6-containing nAChRs would be quite valuable. 
Mapping the binding interface is a major step toward that goal. An increasing collection 
of structural data has provided valuable guidance, but it has been less helpful in revealing the 
subtle features that distinguish particular subtypes. For prototype agonists such as ACh and 
nicotine (structures shown in Figure 1A), the residues comprising the primary and 
complementary binding interfaces are conserved among all α and all β subunits, respectively.12 
Therefore, additional precision is required to understand the functional details of neuronal 
nAChR binding sites.
13
 We have established a strategy based on the incorporation of non-
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canonical amino acids and electrophysiological characterization that allows high precision 
characterization of drug-receptor interactions in nAChRs and related systems.
14
  Application of 
this approach to the α4β2 nAChR – the most common nicotinic receptor in the brain – revealed 
three key binding interactions: a cation-π interaction with α4 Trp149, a hydrogen bond with the 
backbone carbonyl associated with Trp149, and an additional hydrogen bond between nicotine’s 
pyridine nitrogen and a backbone NH in the β2 subunit.
15,16
  The cation-π interaction at Trp149 – 
which is also referred to as TrpB as it lies on the canonical “loop B” of the primary agonist 
binding site – has been observed at homologous aromatic residues throughout the nAChR and 
broader pLGIC families and was later corroborated in recent crystal structures of α4β2 nAChR, 
glycine, and serotonin receptors.
17–21
  Yet, recent work using non-canonical amino acid 
mutagenesis has shown that in the α6β2 receptor, acetylcholine makes a functionally important 
cation-π interaction, but nicotine and TC299423 (an agonist that shows some selectivity for α6β2 
receptors,
22
 structure shown in Figure 1A) do not.
23
  This binding mode differs from the α4β2 
subtype, which suggests the question: what other interactions besides a cation-π interaction at 
Trp149 might be responsible for the binding of nicotine and TC299423 in the α6β2 nAChR? 
 This report investigates the role of a possible hydrogen bond between an agonist’s amine 
moiety and the backbone carbonyl associated with TrpB in α6β2.  While quaternary ammonium 
agonists such as acetylcholine are unable to make a hydrogen bond, such interactions have been 
observed in α4β2 for nicotine and the smoking cessation drugs varenicline (Chantix®) and 
cytisine (Tabex®),
24,25
 all of which contain a protonated amine (ammonium ion) that provides 
the hydrogen bond donor. In each of those instances, evidence of the hydrogen bond was 
accompanied by evidence of a cation-π interaction at TrpB; however, because nicotine was not 
observed to make a strong cation-π interaction at TrpB with α6β2, it was uncertain whether it 
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would make the corresponding hydrogen bond with that tryptophan’s backbone carbonyl.  Here, 
structure-function studies using α-hydroxy acid substitution reveal that nicotine indeed makes a 
functional hydrogen bond with this backbone carbonyl in α6β2.  The interaction is further 
supported and quantified by a double mutant cycle analysis utilizing N’-methylnicotinium. In 
contrast, TC299423 shows at best a weak interaction with this carbonyl. 
Figure 1. A) Agonists used to probe for hydrogen bonds with Trp149-associated backbone 
carbonyl in α6β2.  B,C) Probing H-bonds uses the Tah strategy, which effectively mutates the 
amide backbone into an ester bond.  D) A functional hydrogen bond results in an increase in 
EC50 in the Tah mutant (pink dose-response curve) relative to wild-type (blue). 
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Results and Discussion 
α-hydroxy acid substitution at Thr150 in α6β2
‡
.  All studies make use of the previously 
described α6β2
‡
 construct, which contains mutations far removed from the agonist binding site 
that increase plasma membrane levels, in part, by facilitating transport out of the endoplasmic 
reticulum and to the cell surface.
23
 To probe for a hydrogen bond to a backbone carbonyl, the 
residue at the i+1 position is mutated to the corresponding α-hydroxy acid (Figure 1B).
26
   In 
both α6β2
‡
 and α4β2, the residue i+1 to Trp149 is Thr150.  In the mutation to threonine α-
hydroxy acid (Tah), the amide backbone becomes an ester backbone without affecting the side 
chain (Figure 1C).  It is well established that an ester carbonyl is a significantly weaker hydrogen 
bond acceptor than an amide carbonyl.
27
 In previous studies of several nAChR subtypes, this 
mutation has produced shifts in EC50 ranging from 3-fold to 27-fold.
13
  
The results for substituting α6 Thr150 with Tah are summarized in Table 1. Importantly, 
ACh – which cannot make a conventional hydrogen bond to the backbone carbonyl – shows no 
significant effect. This establishes that the function of the receptor has not been degraded in 
some generic fashion by the backbone mutation. In sharp contrast, nicotine displays a 24-fold 
Table 1. Investigating Hydrogen Bonding at α6β2
‡
 TrpB Carbonyl  
ACh EC50 (µM) nH Imax (µA) Fold-shift N 
Thr 0.16 ± 0.01 1.3 ± 0.1 0.32 - 3.8   10 
Tah 0.20 ± 0.01 0.9 ± 0.1 0.48 - 3.3 1.3 10 
                        
Nicotine EC50 (µM) nH Imax (µA) Fold-shift N 
Thr 0.11 ± 0.01 1.4 ± 0.1 0.19 - 2.7   16 
Tah 2.7 ± 0.1 1.2 ± 0.1 0.09 - 2.7 24 10 
                        
TC299423 EC50 (µM) nH Imax (µA) Fold-shift N 
Thr 0.08 ± 0.01 1.1 ± 0.1 0.21 - 3.6   11 
Tah 0.30 ± 0.01 0.9 ± 0.1 0.12 - 4.1 3.8 13 
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increase in EC50 (loss of function, dose responses shown in Figure 1D), suggesting it makes a 
potent hydrogen bond with the backbone carbonyl of TrpB. Perhaps surprisingly, only a 4-fold 
loss of function was observed for TC299423.  
Quantifying the α6β2
‡
-nicotine Hydrogen Bond. Our results show that perturbing the 
backbone carbonyl at TrpB strongly impacts nicotine activation of the α6β2
‡
 receptor. This is 
highly suggestive of a hydrogen bond, but other explanations are possible. Also, putting an 
energetic value on the proposed hydrogen bond is challenging. A classic technique in 
determining a functional coupling interaction between amino acids in a protein is the double-
mutant cycle analysis.
28–30
  In this type of experiment, the two amino acids of interest are each 
mutated in a way that would attenuate the proposed interaction, both independently (as single-
Figure 2. Schematic of the double-mutant cycle analysis used to confirm and quantify a 
functional hydrogen bond between nicotine at α6β2 receptors. Equations used to calculate Ω 
and ∆∆G values are shown. 
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mutants) and simultaneously (as a double-mutant). If the change in binding seen in the double-
mutant is a simple sum of each single-mutant – that is, if the energetic effects are additive – the 
single-mutant perturbations act independently of each other, and the two amino acids do not 
participate in a functionally coupled interaction.  If, on the other hand, the effect of the double-
mutant proves to be non-additive, the amino acids are considered to be functionally coupled.  
The degree to which the double-mutant is additive or non-additive is expressed by an Ω value, 
which is defined as the product of the wild-type and double-mutant EC50 values divided by the 
product of the single-mutant EC50 values (Figure 2).  An Ω value differing from 1 indicates 
functional coupling between amino acids. As discussed elsewhere, perturbations to EC50 
resulting from mutations at the agonist binding site can be considered to reflect changes in 
agonist binding affinities, allowing an Ω value to be converted to a ∆∆G for the coupling energy 
between amino acids.
29,31–33
 
To assess the nicotine hydrogen bond with the TrpB backbone carbonyl, we designed an 
analog to the double-mutant cycle analysis (schematic shown in Figure 2).  The first mutant in 
the analysis is the T150Tah substitution that results in an amide-to-ester backbone mutation.  The 
second “mutant” uses a nicotine analog, wherein the pyrrolidine nitrogen is methylated to yield 
N’-methylnicotinium (N’MeNic in data tables).  As a quaternary ammonium, this compound is 
similar to ACh in that it is unable to donate a hydrogen bond.  By finding EC50 values for each 
condition – nicotine at wild-type, nicotine at T150Tah, N’-methylnicotinium at wild-type, and 
N’-methylnicotinium at T150Tah – and determining whether or not the double-mutant shows an 
additive loss of function, this mutant cycle will not only further test the hypothesis that nicotine 
makes a hydrogen bond with the backbone carbonyl of Trp149 but will also quantify the strength 
of the hydrogen bond. We have previously used a similar mutant cycle analysis – one mutation 
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being on the protein the other on the drug – to probe the hydrogen bond involving the pyridine N 
of nicotine.
30
 
 As a proof of concept, the double-mutant cycle analysis described above was first 
performed in the α4β2 nAChR, because this subtype is more extensively studied and has a better 
understood binding map for nicotine.  At α4β2, nicotine shows a 27-fold shift in EC50 at the 
T150Tah mutant, a major loss of function (Table 2). When N’-methylnicotinium is tested at the 
wild-type receptor, a 6-fold loss of function is observed.  If these two mutations were 
independent of each other - meaning loss of function was due to an effect other than attenuating 
the proposed hydrogen bond - an additive loss of function would be expected at the double-
mutant close to 160-fold.  Instead, an EC50 of 0.40 µM is observed, which is not meaningfully 
different from the EC50 of N’-methylnicotinium at wild-type (0.62 µM) and only a 4-fold loss of 
function compared to nicotine at the wild-type.  This lack of additivity is quantified with an Ω 
value of 42, which when expressed in free energy terms reveals a ∆∆G value of -2.2 kcal/mol.  
This value is comparable to empirically determined hydrogen bond strengths of N-
methylacetamide aggregates in carbon tetrachloride (∆H
o
 = -4.2 kcal/mol) and benzene (∆H
o
 = -
3.6 kcal/mol).
34,35
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The same approach was taken in α6β2
‡
; as noted above nicotine experiences a 24-fold 
loss of function at T150Tah.  The other single-mutant in this analysis, which is N’-
methylnicotinium at wild-type α6β2
‡
, shows an even larger loss of function, with a 38-fold shift 
in EC50. If these losses in function were not due to hydrogen bonding and instead were 
independent of each other, the double-mutant fold-shift would be additive with a nearly 900-fold 
increase in EC50 with respect to wild-type.  The double-mutant, N’-methylnicotinium at 
T150Tah, has instead an EC50 of 1.2 µM, an 11-fold shift away from wild-type, showing the 
effect is non-additive.  Overall, the mutant cycle has an Ω value of 88 and a ∆∆G of -2.6 
kcal/mol, suggesting nicotine makes a hydrogen bond in α6β2
‡
 that is at least as strong as that 
seen in α4β2.  
Conclusion 
These results reveal an interesting diversity among nAChR subtypes. First, consider the 
binding of nicotine at the two different receptor subtypes – α4β2 and α6β2.  The binding pattern 
for α4β2 is familiar – a strong cation-π interaction to TrpB and a strong hydrogen bond to the 
Table 2. Double Mutant Cycle Analysis of the Nicotine-TrpB Carbonyl Hydrogen Bond 
α4β2 Agonist T150 EC50 (µM) nH Imax (µA) Fold-shift N 
WT Nic Thr 0.10 ± 0.01 1.4 ± 0.2 0.05 - 1.2 1 15 
Mut1 Nic Tah 2.7 ± 0.1 1.3 ± 0.1 0.11 - 1.2 27 6 
Mut2 N'MeNic Thr 0.62 ± 0.03 1.2 ± 0.1 0.02 - 0.60 6.2 10 
Mut1,2 N'MeNic Tah 0.40 ± 0.04 1.1 ± 0.1 0.08 - 0.42 4.0 12 
                        Ω 42 
∆∆G (kcal/mol) -2.2 
  
α6β2
‡
 Agonist T150 EC50 (µM) nH Imax (µA) Fold-shift N 
WT Nic Thr 0.11 ± 0.01 1.4 ± 0.1 0.19 - 2.7 1 16 
Mut1 Nic Tah 2.7 ± 0.1 1.1 ± 0.1 0.09 - 2.7 24 10 
Mut2 N'MeNic Thr 4.2 ± 0.2 1.0 ± 0.1 0.10 - 2.1 38 11 
Mut1,2 N'MeNic Tah 1.1 ± 0.1 0.9 ± 0.1 0.08 - 1.1 11 10 
                        Ω 88 
∆∆G (kcal/mol) -2.6 
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associated backbone carbonyl. In α6β2 the cation-π interaction is absent, and so one might 
conclude that the drug had moved away from TrpB. We now find that nicotine makes a 
comparably strong hydrogen bond to the backbone carbonyl in α6β2 – a surprising and 
intriguing binding pattern. Another interesting difference is seen in the consequences of 
quaternizing nicotine – making it more like the natural agonist ACh. In α4β2 this has a modest 
effect on potency (only a 6-fold shift), but in α6β2 the impact is markedly larger (a 37-fold 
shift), again suggesting an altered binding orientation. 
Finally, our results suggest that TC299423 interacts very weakly with TrpB. There is no 
evidence for a cation-π interaction, and backbone mutation has a much smaller effect than was 
seen for nicotine. These findings should provide valuable guidance to efforts to develop subtype-
specific drugs targeting α6-containing nAChRs.  
Corresponding Author:  Dennis A. Dougherty, dadougherty@caltech.edu 
Acknowledgements. This work was supported by the NIH (NS 34407, DA019375).  MRP was 
supported by an NIH/NRSA training grant: 5 T32 GM07616.  We thank Merouane Bencherif 
and Daniel Yohannes (Targacept) for gifts of TC299423. 
Materials and Methods 
Molecular Biology 
Rat α6, α4, and β2 nAChRs were in the pGEMhe vector, a cDNA plasmid optimized for protein 
expression in Xenopus oocytes.  Site-directed mutagenesis was performed by PCR using the 
Stratagene QuikChange protocol and primers ordered from Integrated DNA Technologies 
(Coralville, IA).  Circular cDNA was linearized with SbfI (New England Biolabs, Ipswich, MA) 
and then transcribed in vitro using T7 mMessage mMachine kit (Life Technologies, Santa Clara, 
CA), with a purification step after each process (Qiagen, Valencia, CA).  Final concentrations 
were quantified by UV spectroscopy. 
Ion Channel Expression and α-hydroxy Acid Incorporation 
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For optimized expression, α4L9’Aβ2 and α6L9’Sβ2L9’SLFM/AAQA were used as the “wild-type” 
receptor which further mutations are compared against.  These are referred to as α4β2 and α6β2
‡ 
respectively throughout for clarity.  For nonsense suppression-based, site-specific non-canonical 
amino acid incorporation, the cyanomethylester form of threonine α-hydroxy was first 
synthesized, coupled to the dinucleotide dCA, and enzymatically ligated to UAG-suppressor 74-
mer THG73 tRNACUA as previously described.
13
  The product was verified by MALDI time-of-
flight mass spectrometry on a 3-hydroxypicolinic acid matrix.  Xenopus laevis oocytes (stage V to 
VI) were sourced from both a Caltech facility and Ecocyte Bio Science (Austin, TX).  The Tah-
tRNA was injected along with T150UAG mRNA into oocytes at a 1:1 volume ratio, with an 
α6:β2 mRNA mass ratio of 10:1 or an α4:β2 mass ratio of 1:3, resulting in 25 ng each of mRNA 
and tRNA injected per cell.  Cells were incubated 24-48 hours at 18
o
C in ND96 solution (96 mM 
NaCl, 2mM KCl, 1 mM MgCl2, and 5mM HEPES, pH 7.5) enriched with theophylline, sodium 
pyruvate, gentamycin, and horse serum.  The fidelity of incorporation of Tah was confirmed by 
charging tRNA with Thr in a wild-type recovery experiment.  Data from these experiments 
(reported as Thr in the data tables above) matched wild-type data, reported in previous studies.  A 
read-through/reaminoacylation test serves as a negative control wherein a 76-mer tRNA is 
injected alongside mRNA.  Lack of current proved no detectable re-aminoacylation at the Thr150 
site. 
N’-methylnicotinium Synthesis 
Synthesis of N’-methylnicotinium was based on previously reported methods.
36
  All reagents 
were purchased from Sigma Aldrich (St. Louis, MO).  In a roundbottom flask, 19.8 mL of (-)-
nicotine were added to 250 mL of acetonitrile and excess sodium carbonate.  Then, 5.76 mL of 
methyl iodide were added dropwise while stirring.  The reaction was stirred at room temperature 
for three days.  The reaction solution was filtered by vacuum and solids were discarded.  Solvent 
from the filtrate was removed by rotary evaporation until tan oil remained. Deionized water, 50 
mL, was added to the oil and dissolved forming an orange solution.  Continuous chloroform 
extraction was performed on the orange solution for five days.  The aqueous layer was isolated 
and solvent was removed by rotary evaporation upon which crystals formed.  Product was 
recrystallized three consecutive times with hot isopropanol for an over 40% yield.  Further 
purification was achieved by iterative preparative HPLC (Waters, Milford, MA) using a 100% 
water solvent profile. 
1
H NMR (500 MHz, Acetonitrile-d3) δ 8.80 (dd, J = 2.5, 0.8 Hz, 1H), 8.71 (dd, J = 4.8, 1.6 Hz, 
1H), 8.12 – 8.00 (m, 1H), 7.50 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 5.06 (dd, J = 11.5, 8.0 Hz, 1H), 
3.95 – 3.69 (m, 2H), 3.12 (s, 3H), 2.75 (s, 3H), 2.74 – 2.63 (m, 1H), 2.57 – 2.42 (m, 1H), 2.39 – 
2.19 (m, 2H). 
Whole-Cell Electrophysiological Characterization 
Acetylcholine chloride and (-)-nicotine tartrate were purchased from Sigma Aldrich (St Louis, 
MO), while TC299423 (Targacept) was a generous gift.  N’-methylnicotinium iodide was 
prepared according to the procedure above.  Agonist-induced currents were recorded in two-
electrode voltage-clamp mode using the OpusXpress 6000A (Molecular Devices, Sunnyvale, CA) 
at a holding potential of -60 mV in a running buffer of Ca
2+
-free ND96.  Agonists were prepared 
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in Ca
2+
-free ND96 and delivered to cells via a 1 mL application over 15 s followed by a 2 min 
wash.  EC50 values describe the concentration required to activate half the receptors expressed on 
the cell surface and were determined through dose response experiments, while fold-shifts in 
EC50 are equal to the mutant EC50 divided by wild-type EC50.  To derive an EC50 value, data from 
dose-response experiments were normalized to the maximum current-response, averaged, and fit 
to the Hill equation using Kaleidagraph (Synergy Software, Reading PA), though data are 
visualized here with Prism (GraphPad Software, La Jolla, CA).  Error bars, as well as reported 
errors for EC50 and Hill coefficient (nH) are presented as SEM. 
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